Novel Mouse Cell Lines and In Vivo Models for Human High-Grade Neuroendocrine Lung Carcinoma, Small Cell Lung Carcinoma (SCLC), and Large Cell Neuroendocrine Carcinoma (LCNEC).
LCNEC
SCLC
allograft
cell lines
syngeneic
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
18 Oct 2023
18 Oct 2023
Historique:
received:
20
09
2023
revised:
11
10
2023
accepted:
11
10
2023
medline:
30
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
There is a clear need to expand the toolkit of adequate mouse models and cell lines available for preclinical studies of high-grade neuroendocrine lung carcinoma (small cell lung carcinoma (SCLC) and large cell neuroendocrine carcinoma (LCNEC)). SCLC and LCNEC are two highly aggressive tumor types with dismal prognoses and few therapeutic options. Currently, there is an extreme paucity of material, particularly in the case of LCNEC. Given the lack of murine cell lines and transplant models of LCNEC, the need is imperative. In this study, we generated and examined new models of LCNEC and SCLC transplantable cell lines derived from our previously developed primary mouse LCNEC and SCLC tumors. RNA-seq analysis demonstrated that our cell lines and syngeneic tumors maintained the transcriptome program from the original transgenic primary tumor and displayed strong similarities to human SCLC or LCNEC. Importantly, the SCLC transplanted cell lines showed the ability to metastasize and mimic this characteristic of the human condition. In summary, we generated mouse cell line tools that allow further basic and translational research as well as preclinical testing of new treatment strategies for SCLC and LCNEC. These tools retain important features of their human counterparts and address the lack of LCNEC disease models.
Identifiants
pubmed: 37894963
pii: ijms242015284
doi: 10.3390/ijms242015284
pmc: PMC10607103
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Instituto de Salud Carlos III
ID : PI21/00764; PI21/00208; PI15/00993; CB16/12/00228/CIBERONC
Références
J Natl Cancer Inst. 2010 Sep 8;102(17):1310-21
pubmed: 20679594
Mol Cell Oncol. 2020 Jan 7;7(2):1702413
pubmed: 32158917
Transl Lung Cancer Res. 2018 Feb;7(1):32-49
pubmed: 29535911
Cell Rep. 2016 Jul 19;16(3):644-56
pubmed: 27373157
Nat Rev Cancer. 2019 May;19(5):289-297
pubmed: 30926931
Medicina (Kaunas). 2021 Jan 28;57(2):
pubmed: 33525370
J Thorac Oncol. 2015 Apr;10(4):553-64
pubmed: 25675280
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Cancer Cell. 2011 Feb 15;19(2):244-56
pubmed: 21316603
Transl Lung Cancer Res. 2018 Feb;7(1):21-31
pubmed: 29535910
Br J Pharmacol. 2019 Feb;176(3):436-450
pubmed: 30427531
Semin Cancer Biol. 2022 Nov;86(Pt 2):450-462
pubmed: 35609720
ESMO Open. 2022 Apr;7(2):100408
pubmed: 35279527
Cell Rep. 2020 Oct 20;33(3):108296
pubmed: 33086069
Cell. 2016 Jul 14;166(2):328-342
pubmed: 27374332
Cancer Cell. 2021 Mar 8;39(3):346-360.e7
pubmed: 33482121
EMBO Mol Med. 2021 Jan 11;13(1):e13122
pubmed: 33296145
Transl Lung Cancer Res. 2020 Oct;9(5):2233-2244
pubmed: 33209646
Cancers (Basel). 2022 Jul 28;14(15):
pubmed: 35954335
Nat Genet. 2006 May;38(5):500-1
pubmed: 16642009
Cold Spring Harb Perspect Med. 2021 Apr 1;11(4):
pubmed: 32513672
Genome Biol. 2014;15(12):550
pubmed: 25516281
Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22300-22306
pubmed: 31611390
Genes Dev. 2015 Aug 1;29(15):1587-92
pubmed: 26215568
Transl Lung Cancer Res. 2017 Oct;6(5):513-529
pubmed: 29114468
Cancers (Basel). 2020 Dec 22;13(1):
pubmed: 33375066
Genome Biol. 2003;4(5):P3
pubmed: 12734009
Genes Dev. 2020 Aug 1;34(15-16):1017-1032
pubmed: 32747478
Nat Rev Dis Primers. 2021 Jan 14;7(1):3
pubmed: 33446664
J Clin Med. 2022 Mar 07;11(5):
pubmed: 35268551
PLoS One. 2007 Nov 21;2(11):e1195
pubmed: 18030330
Genome Biol. 2003;4(10):R70
pubmed: 14519205
Nature. 2015 Aug 6;524(7563):47-53
pubmed: 26168399
Nat Commun. 2018 Mar 13;9(1):1048
pubmed: 29535388
J Clin Invest. 2016 Jul 1;126(7):2610-20
pubmed: 27294525
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641